On September 9, 2021 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported that it will host a data update webcast for investors and analysts during the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting 2021, September 17, 2021 at 1:30 p.m. ET (Press release, Gritstone Oncology, SEP 9, 2021, View Source [SID1234592012]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data in advanced solid tumors which is being presented during a mini- oral presentation at ESMO (Free ESMO Whitepaper) 2021, in addition to data from the SLATE v1 shared neoantigen immunotherapy program in KRAS mutant advanced solid tumors.
Presenters:
Andrew Allen, M.D., Ph.D., Gritstone’s chief executive officer, will provide a brief overview of the company, its neoantigen directed approach to immunotherapy, and next steps for the GRANITE and SLATE oncology programs
Daniel Catenacci, M.D., assistant professor of medicine, University of Chicago, will review the most recent GRANITE data
Thierry Andre, M.D., professor of medical oncology, St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, will discuss the current treatment landscape and unmet medical need in treating patients with microsatellite stable colorectal cancer (MSS-CRC)
The presentation will be followed by a Q&A session.
To register for the webinar, please click here. The call and accompanying slides will be webcast live on the "Events" page under the "Investors & Media" section of the company’s website at www.gritstone.com. A replay of the webcast will be accessible at the same link approximately one day after its completion.
Daniel Catenacci, M.D., is an associate professor of medicine and director of the gastrointestinal oncology program at the University of Chicago. He serves as the assistant director of Translational Research in the Comprehensive Cancer Center. In addition to his clinical practice as an adult gastrointestinal medical oncologist, Dr. Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. His bench-to-bedside translational research has an overarching goal to validate and improve personalized treatment, immunotherapy, and precision medicine for gastroesophageal cancer and other GI cancers. Additionally, Dr. Catenacci designs and executes novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries. Dr. Catenacci serves as an associate editor for the Journal of American Medical Association Network Open (JAMA Netw Open) and is on the editorial board of the Journal of Clinical Oncology Precision Oncology (J Clin Oncol PO).
Thierry André, M.D., is a professor of medical oncology at the University Pierre et Marie Curie (UMPC), Paris VI, and head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris. He is the founding member and general secretary of the GERCOR (Multidisciplinary Oncology Research Group) and leads the colorectal task force of GERCOR and also serves as a member of the Adjuvant Colon Cancer Endpoints (ACCENT) group. Dr. André’s main research interest is in gastrointestinal malignancies. Dr. André is a member of several scientific organizations including the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper), and was chairman of the GI Cancer Board for Research of the French National Institute (INCA).